Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acer saccharinum pollen is an allergen extract derived from the pollen of the silver maple tree (*Acer saccharinum*). It is utilized as a biological product for both the diagnosis of allergic sensitivity via skin testing and the treatment of allergic rhinitis, allergic conjunctivitis, and seasonal asthma through allergen immunotherapy (desensitization). The extract contains the specific proteins (allergens) found in silver maple pollen, which, when administered in gradually increasing doses, help to modulate the patient's immune response. This process involves shifting the immune system from a Th2-mediated allergic reaction toward a more tolerant state, characterized by the induction of regulatory T-cells and a shift in antibody production from IgE to IgG4.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acer saccharinum pollen.